Literature DB >> 12401556

Norepinephrine transporter gene (NET) variants in patients with panic disorder.

P G Sand1, T Mori, C Godau, G Stöber, P Flachenecker, P Franke, M M Nöthen, J Fritze, W Maier, K-P Lesch, P Riederer, H Beckmann, J Deckert.   

Abstract

Several lines of evidence suggest that catecholamines, especially norepinephrine, are implicated in the etiology and/or symptomatology of panic disorder (PD). At the cellular level, functional noradrenergic neurotransmission depends on synaptic reuptake of norepinephrine as mediated by the norepinephrine transporter (NET). A pharmacological target of agents with an established anti-panic efficacy, e.g. tricyclic antidepressants, the NET is of particular interest in PD. We investigated the NET gene for the presence of 6 naturally occurring exonic sequence variants, 5 of which give rise to amino acid substitutions (Val69Ile, Thr99Ile, Val245Ile, Val449Ile and Gly478Ser) in a population of 87 patients with PD and 89 healthy controls. Except for a silent substitution (G1287A), overall frequencies of variant alleles were low (< or =0.016). None of the variants under study was found to be associated with PD regardless of an additional diagnosis of agoraphobia. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401556     DOI: 10.1016/s0304-3940(02)00984-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

Review 1.  Candidate genes in panic disorder: meta-analyses of 23 common variants in major anxiogenic pathways.

Authors:  A S Howe; H N Buttenschøn; A Bani-Fatemi; E Maron; T Otowa; A Erhardt; E B Binder; N O Gregersen; O Mors; D P Woldbye; K Domschke; A Reif; J Shlik; S Kõks; Y Kawamura; A Miyashita; R Kuwano; K Tokunaga; H Tanii; J W Smoller; T Sasaki; D Koszycki; V De Luca
Journal:  Mol Psychiatry       Date:  2015-09-22       Impact factor: 15.992

2.  The norepinephrine transporter gene is a candidate gene for panic disorder.

Authors:  H N Buttenschøn; A S Kristensen; H N Buch; J H Andersen; J P Bonde; M Grynderup; A M Hansen; H Kolstad; A Kaergaard; L Kaerlev; S Mikkelsen; J F Thomsen; P Koefoed; A Erhardt; D P D Woldbye; A D Børglum; O Mors
Journal:  J Neural Transm (Vienna)       Date:  2011-03-18       Impact factor: 3.575

3.  Lack of association between the norepinephrine transporter gene and major depression in a Han Chinese population.

Authors:  Chuan-Chia Chang; Ru-Band Lu; Chih-Lun Chen; Chi-Ming Chu; Hsin-An Chang; Cheng-Chang Huang; Yi-Lin Huang; San-Yuan Huang
Journal:  J Psychiatry Neurosci       Date:  2007-03       Impact factor: 6.186

4.  A Genetic Susceptibility Mechanism for Major Depression: Combinations of polymorphisms Defined the Risk of Major Depression and Subpopulations.

Authors:  Yanfang Wang; Ning Sun; Suping Li; Qiaorong Du; Yong Xu; Zhifeng Liu; Kerang Zhang
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

5.  The norepinephrine transporter gene is associated with the retardation symptoms of major depressive disorder in the Han Chinese population.

Authors:  Xinrong Li; Ning Sun; Yong Xu; Yanfang Wang; Suping Li; Qiaorong Du; Juyi Peng; Jinxiu Luo; Kerang Zhang
Journal:  Neural Regen Res       Date:  2012-09-05       Impact factor: 5.135

Review 6.  Neuroinflammation-Associated Alterations of the Brain as Potential Neural Biomarkers in Anxiety Disorders.

Authors:  Eunsoo Won; Yong-Ku Kim
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

7.  A functional genetic variation of SLC6A2 repressor hsa-miR-579-3p upregulates sympathetic noradrenergic processes of fear and anxiety.

Authors:  L G Hommers; J Richter; Y Yang; A Raab; C Baumann; K Lang; M A Schiele; H Weber; A Wittmann; C Wolf; G W Alpers; V Arolt; K Domschke; L Fehm; T Fydrich; A Gerlach; A T Gloster; A O Hamm; S Helbig-Lang; T Kircher; T Lang; C A Pané-Farré; P Pauli; B Pfleiderer; A Reif; M Romanos; B Straube; A Ströhle; H-U Wittchen; S Frantz; G Ertl; M J Lohse; U Lueken; J Deckert
Journal:  Transl Psychiatry       Date:  2018-10-19       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.